NCT03565120

Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer

The Efficacy and Toxicity of Aggressive Thoracic Radiotherapy for Stage Ⅳ Non-Small Cell Lung Cancer Patients With Controlled Extrathoracic Disease

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: yu gengsheng · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This phase II trial studies the safety and efficacy of aggressive thoracic radiotherapy in treating patients with non-small cell lung cancer that has not progressed after the first line systemic therapy. In this trial, patients with stage Ⅳ non small cell lung cancer who did not progress after first line systemic therapy will receive the aggressive thoracic radiotherapy, and the safety and efficacy of aggressive thoracic radiotherapy will be evaluated. The primary end points of the study are overall survival (OS), the secondary end points are local control rate, local progression free survival(LPFS), PFS, and toxicity and quality of life(QOL).

Conditions

• Carcinoma, Non-Small-Cell Lung
• Stage IV
• Thoracic Radiotherapy

Interventions

Type	Name	Description
RADIATION	Aggressive Thoracic Radiotherapy	The target of the radiotherapy includes primary tumor and the locoregional positive lymph nodes, with a dose(BED)≥53Gray(Gy)

Timeline

• Start date: 2018-12-10
• Primary completion: 2023-12-01
• Completion: 2023-12-01
• First posted: 2018-06-21
• Last updated: 2018-12-26

Locations

1 site across 1 country: China